Mechanisms of Resistance to Chemotherapy in Gastric Cancer.

Marin JJ, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales JM, Macias RI.

Anti-Cancer Agents In Medicinal Chemistry. 2016; 16: 318-334. FI: 2,598 (Q2).

Bile Acids in Physiology, Pathology and Pharmacology.

Marin JJ, Macias IR, Briz O, Banales JM, Monte MJ.

Current Drug Metabolism. 2016; 17: 4-29. FI: 2,659 (Q2).

“Fast track” and intestinal surgery for Crohn’s disease: Factors associated with prolonged hospital stay.

Enriquez-Navascués JM, Elorza G, Placer C, Timoteo A, Velaz L, Borda N, Saralegui Y.

Cirugia Española. 2016; 94: 531-536. FI: 1,276 (Q3).

NLRP3 inflammasome activation by microbial products leads to IL-18 synthesis and impaired epithelial barrier function in cholangiocytes.

Maroni L, Agostinelli L, Saccomanno S, Mingarelli E, Rychlicki C, De Minicis S, Banales JM, Benedetti A, Baroni GS, Marzioni M.

Digestive And Liver Disease. 2016; 48: 12-12. FI: 3,061 (Q2).

Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study.

González CA, Sanz-Anquela JM, Companioni O, Bonet C, Berdasco M, López C, Mendoza J, Martín-Arranz MD, Rey E, Poves E, Espinosa L, Barrio J, Torres MÁ, Cuatrecasas M, Elizalde I, Bujanda L, Garmendia M, Ferrández Á, Muñoz G, Andreu V, Paules MJ, Lario S, Ramírez MJ, Study group, Gisbert JP.

Journal Of Gastroenterology And Hepatology. 2016; 31: 953-958. FI: 3,452 (Q2).

Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening.

Alvarez-Urturi C, Andreu M, Hernandez C, Perez-Riquelme F, Carballo F, Ono A, Cruzado J, Cubiella J, Hernandez V, Mao CG, Perez E, Salas D, Andrés M, Bujanda L, Portillo I, Sarasqueta C, Quintero E, Morillas JD, Lanas A, Sostres C, Augé JM, Castells A, Bessa X, COLONPREV study investigators.

Digestive And Liver Disease. 2016; 48: 542-551. FI: 3,061 (Q2).

Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study).

Piqué N, Ponce M, Garrigues V, Rodrigo L, Calvo F, de Argila CM, Borda F, Naranjo A, Alcedo J, José Soria M, Rey E, Bujanda L, Gisbert JP, Suarez D, Calvet X, Ponce J, PRESS Study Group.

United European Gastroenterology Journal. 2016; 4: 229-235. FI: 3,673 (Q2).

Immunotherapy in colorectal cancer: What have we learned so far?

Sanchez-Castañón M, Er TK, Bujanda L, Herreros-Villanueva M.

Clinica Chimica Acta. 2016; 460: 78-87. FI: 2,873 (Q2).

Colorectal cancer health services research study protocol: The CCR-CARESS observational prospective cohort project.

Quintana JM, Gonzalez N, Anton-Ladislao A, Redondo M, Bare M, Fernandez de Larrea N, Briones E, Escobar A, Sarasqueta C, Garcia-Gutierrez S, Aguirre U, REDISSEC-CARESS/CCR group.

Bmc Cancer. 2016; 16: 435-435. FI: 3,288 (Q2).

LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis.

Assadi G, Saleh R, Hadizadeh F, Vesterlund L, Bonfiglio F, Halfvarson J, Torkvist L, Eriksson AS, Harris HE, Sundberg E, D'Amato M.

Genes And Immunity. 2016; 17: 261-264. FI: 2,524 (Q2).